NURL — Neural Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$2.66m
- CA$2.41m
Annual income statement for Neural Therapeutics, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 1.82 | 1.07 | 0.656 |
| Operating Profit | -1.82 | -1.07 | -0.656 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -1.82 | -1.08 | -0.666 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -1.82 | -1.08 | -0.666 |
| Net Income Before Extraordinary Items | |||
| Net Income | -1.82 | -1.08 | -0.666 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -1.82 | -1.08 | -0.666 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.008 | -0.014 | -0.008 |